Predictors of adverse course of COVID-19 in patients with acute abdominal surgical pathology
Main Article Content
Abstract
The continuous wave-like morbidity increasing of coronavirus disease in 2019 (COVID-19), the emergence of different strains of the virus has contributed to the search for new ways in diagnostic algorithms and methods of treatment of such patients. Expert opinion of the International Society of Thrombosis and Haemostasis on the predictors of adverse COVID-19 encourages the search for modern ways to determine the degree of coagulopathy. Determination of prothrombin time clearance, D-dimer and platelet count in patients, whom was performed surgery, is one way to stratify the risk of venous thromboembolism. The results of surgical treatment of 504 patients in the surgical center of Lviv Emergency Medical Hospital for the 2019-2021 were analyzed. Slightly dominated by man – 52.7%. The age of patients ranged from 21 to 85 years (mean – 62.1±21.2). As a result of the scientific study, 36 (7.14%) patients operated on with abdominal pathology and confirmed diagnosis of COVID-19 were analyzed in detail. 27 (23.1%) patients were in the intensive care unit, 14 of them (51.8%) with invasive lung ventilation – 11 (78.6%), the average bed-day in intensive care was 7.2 days. 14 (38.9%) patients died, and autopsies were performed in 13 (92.8%). Cause of death: multiple organ failure, pulmonary embolism, septic complications. Introduction. The continuous wave-like morbidity increasing of coronavirus disease in 2019 (COVID-19), the emergence of different strains of the virus has contributed to the search for new ways in diagnostic algorithms and methods of treatment of such patients. Since December 2019, more than 240 million patients and 4.8 million deaths caused by coronavirus SARS-CoV-2 have been registered, a third of whom, according to many authors, have been diagnosed with thrombosis in various locations. The development of coagulopathy and ICE syndrome in coronavirus-infected surgical patients is a special problem, because cytokine distress, hypoxia, endothelin dysfunction, hypercoagulation, thrombosis are potentiated [1,3,6,8]. Expert opinion of the International Society of Thrombosis and Haemostasis (ISTH) on the predictors of adverse COVID-19 encourages the search for modern ways to determine the degree of coagulopathy. Determination of prothrombin time clearance, D-dimer and platelet count in patients, whom was performed surgery, is one way to stratify the risk of venous thromboembolism (VT). And some publications on septic coagulopathy [2,3,5,6,7] additional monitoring of fibrinogen levels, especially their reduction, may be useful in calculating thrombosis risks in surgical patients with coronavirus disease. The aim of the study was to establish the diagnostic value of thrombosis markers in patients with acute abdominal surgical pathology infected coronavirus and to predict the course of the disease. The data of the study 1494 autopsies conducted in our clinic from 1990 to 2000 are noteworthy, as we note a certain change in the ratio of the causes of death of patients in a surgical hospital. Thus, during the SARS-CoV-2 pandemic, the predominant cause of death in patients with acute abdominal surgical pathology was respiratory failure and thromboembolic complications. However it should be noted that some caution of doctors who formulated the final diagnosis because more than half of the dead, sometimes unreasonably, in the concomitant diagnosis indicated pulmonary embolism. Taking into account the opinion of ISTH experts, we have studied certain indicators of coagulopathy during the postoperative period and created an algorithm for the management of patients with COVID-19. The D-dimers dynamics, total fibrinogen, prothrombin time and platelet count were evaluated and subjected to multifactorial analysis by multiple regression. Thus, the significant difference between the groups of recovered and dead was: for D-dimers – an increasing of 3.4 times (p-0.193), for prothrombin time – an increasing of 2.3 times (p-0.454), for fibrinogen – a decreasing of 2.1 time (0.491) and for platelets – a decreasing of 1.7 times (p-0.567). According the studied data, the algorithm for predicting the unresponsive course of the postoperative period in patients with acute surgical abdominal pathology infected with coronavirus type SARS-CoV-2 was modeled. The risk group for fatal thromboembolic complications should include patients with significantly elevated D-dimer, prolonged thromboplastin time, platelet count < 100*109/1 and fibrinogen < 2 g/l. In this case, in our opinion, it is advisable to use more aggressive therapeutic regimens, namely: observation in the intensive care unit, daily monitoring of coagulopathy, the use of therapeutic doses of anticoagulants and possible administration of blood products.
Article Details
References
Tang, N., Li, D., Wang, X., & Sun, Z. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis, 18(4), 844-847. https://doi.org/10.1111/jth.14768
Taylor Jr, F. B., Toh, C. H., Hoots, K. W., Wada, H., & Levi, M. (2001). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thrombosis and haemostasis, 86(11), 1327-1330. https://doi.org/10.1055/s-0037-1616068
Levi, M., Toh, C. H., Thachil, J., & Watson, H. G. (2009). Guidelines for the diagnosis and management of disseminated intravascular coagulation. British journal of haematology, 145(1), 24-33. https://doi.org/10.1111/j.1365-2141.2009.07600.x
Bikdeli, B., Madhavan, M. V., Jimenez, D., Chuich, T., Dreyfus, I., Driggin, E., & Lip, G. Y. (2020). COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. Journal of the American college of cardiology, 75(23), 2950-2973. https://doi.org/10.1016/j.jacc.2020.04.031
McIntosh, K., Hirsch, M. S., & Bloom, A. (2020). Coronavirus disease 2019 (COVID-19). UpToDate Hirsch MS Bloom, 5(1), 873. https://www.cmim.org/PDFcovid/Coronavirusdisease2019COVID-19UpTo Date2.pdf
Caprini, J. A. (2005). Thrombosis risk assessment as a guide to quality patient care. Disease-a-Month, 51(2-3), 70-78. https://www.cardinalhealth.com/content/dam/corp/products/professional-products/ous-patient-recovery/documents/cardinal-health-thrombosis-risk-assessment1.pdf
Thachil, J., Tang, N., Gando, S., Falanga, A., Cattaneo, M., Levi, M., & Iba, T. (2020). ISTH interim guidance on recognition and management of coagulopathy in COVID‐19. Journal of Thrombosis and Haemostasis, 18(5), 1023-1026. https://doi.org/10.1111/jth.14768
Spiezia, L., Boscolo, A., Poletto, F., Cerruti, L., Tiberio, I., Campello, E., ... & Sun, Z. (2020). COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thrombosis and haemostasis, 120(06), 998-1000. https://doi.org/10.1055/s-0040-1710018
